“AmpliPhi Biosciences is developing its leading position in the application of bacteriophage technology to control human disease.”
AmpliPhi Biosciences is a biopharmaceutical company focused on the development of an internally generated pipeline of naturally occurring viruses called bacteriophage (phage) for the treatment of bacterial infection. Phage-based therapy provides a unique and proven approach to treating a wide variety of bacterial infections and in particular, drug-resistant strains of bacteria that are commonly found in the hospital setting. We have built a drug development and manufacturing platform designed to allow rapid development and production of multiple phage-based therapies. Our plan and success relies on our ability to identify and develop selected phage to eradicate targeted bacterial infections across a wide range of bacterial disease. Initially our phage discovery and development platform will focus efforts in acute and chronic lung, sinus and gastrointestinal (GI) infections.
AmpliPhi maintains operations in Richmond, Virginia in the United States, in Colworth Science Park, near London in the United Kingdom, and outside Sydney, NSW, Australia.
April 17th 2013
AmpliPhi Establishes Collaboration with IntrexonMore
February 04th 2013
AmpliPhi Receives Notice of Allowance on Key Patent for its Bacteriophage TherapyMore
November 13th 2012
AmpliPhi and Special Phage Services Complete MergerMore
October 19th 2012
Ampliphi Presents Encouraging Pre-Clinical Data on Phage Therapies to Treat Bacterial Lung InfectionMore
October 12th 2012
AmpliPhi CSO Dr. David Harper presents at NACFC 2012More